Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.
Epidermal Growth Factor Receptor and Its Applications - The discovery of growth factors won the Nobel Prize in Medicine in 1986, implying their importance. Epidermal growth factor receptor, EGFR, one of such factors, exists on cell surface and is activated by binding of its specific ligands. EGFR is a member of the receptor tyrosine kinase family whose members play a critical role in oncogenesis. Mutations affecting EGFR expression or activity could result in cancers, ...
National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.
EGF (Epidermal Growth Factor) is a small 53 amino acid residue protein that is involved in normal cell growth, oncogenesis, and wound healing. This protein shows both strong sequential and functional homology with hTGF-Alpha (human type-Alpha Transforming Growth Factor), which is a competitor for EGF receptor sites. EGF binds to a specific high-affinity, low-capacity receptor on the surface of responsive cells known as EGFR (Epidermal growth factor receptor).
An image of a protein called EGFR (epidermal growth factor receptor) in human cells viewed under a microscope. EGFR, which is shown in green, is localized to the cell's membrane. The cell's nucleus is shown in blue.
Erlotinib is an EGFR inhibitor. The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth factor receptor(EGFR) tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer.